<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04412902</url>
  </required_header>
  <id_info>
    <org_study_id>109053-E</org_study_id>
    <nct_id>NCT04412902</nct_id>
  </id_info>
  <brief_title>Predictors of Recurrence for High Risk Endometrial Cancer Patients</brief_title>
  <official_title>Predictors of Recurrence for High Risk Endometrial Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Far Eastern Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Far Eastern Memorial Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will analyze whether there is any difference in recurrence and survival rates
      among the patients who received different adjuvant therapies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The incidence of endometrial cancer is gradually increasing nowaday. The postoperative
      treatment of high-risk endometrial cancer is also inconsistent. Besides, the recurrence of
      high-risk endometrial cancer is high. Our retrospective study will analyze the factors
      associated with recurrence of endometrial cancer, especially for different adjuvant
      therapies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 25, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Factors affecting overall survival</measure>
    <time_frame>10 years</time_frame>
    <description>Factors affecting overall survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Factors affecting progression-free survival</measure>
    <time_frame>10 years</time_frame>
    <description>Factors affecting progression-free survival</description>
  </secondary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>High-risk Endometrial Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
    <description>Adjuvant chemotherapy and/or radiotherapy</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All high risk endometrial cancer patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients with high risk stage I endometrial cancer and all patients with stage II
             and stage III endometrial cancer and who underwent therapy in Far Eastern Memorial
             Hospital from 2009/01/01~2019/09/17.

        Exclusion Criteria:

          -  Patients with stage I endometrial cancer do not have high risk factors.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>high risk endometrial cancer patients</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sheng-Mou Hsiao, MD</last_name>
    <phone>+886919302632</phone>
    <email>smhsiao2@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Obstetrics and Gynecology, Far-Eastern Memorial Hospital</name>
      <address>
        <city>Banqiao</city>
        <state>New Taipei</state>
        <zip>22050</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheng-Mou Hsiao, M.D.</last_name>
      <phone>+886-2-89667000</phone>
      <phone_ext>1818</phone_ext>
      <email>smhsiao2@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 31, 2020</study_first_submitted>
  <study_first_submitted_qc>May 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2020</study_first_posted>
  <last_update_submitted>May 31, 2020</last_update_submitted>
  <last_update_submitted_qc>May 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Far Eastern Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Sheng-Mou Hsiao</investigator_full_name>
    <investigator_title>Chief of Department of Obstetrics &amp; Gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

